30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review: Companies New on Our Radar in 2018

We’re constantly coming across new companies, be they new customers or new faces at meetings. The pool of your peers just keeps growing, and it’s our mission to keep you aware of them. Here’s a selection of those we identified throughout 2018. All five major market segments are represented, and quite a geographical mix: Denmark, Finland, Israel, Italy and the U.S.

2018 Year in Review: Revenue Projections and Technology Trends

In November, we published our downloadable report, 2018 Revenue Projections: Companies Over $200 Million, for the 25 largest orthopaedic companies. Sales for these 25 companies account for ~80% of the worldwide orthopaedic market. We project that these companies will combine for $41 billion in 2018 revenue, +3% vs. 2017.

Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued

As noted in Part I of our quarterly revenue coverage, robotics and enabling technology in general continued to be a major theme supporting growth for publicly-traded companies.

Investors Prioritize Care Delivery, Post-Revenue Companies

Extremities, sports medicine, digital health and the hospital supply chain remain attractive areas for orthopaedic innovation, according to investors who spoke during this year's Musculoskeletal New Ventures Conference. This seems like a natural course, with extremities and sports medicine being high-growth segments of orthopaedics and innovations in digital health and supply chain routinely mentioned as solutions to complex industry challenges. The sentiment that we took away from the discussion was optimism about the number of investment opportunities available, and about orthopaedics as a whole.

Medartis: Profile of a Newly-Public Orthopaedic Company

Medartis went public on the SIX Swiss Exchange in March, securing proceeds to fund product development, international expansion and potential acquisitions. Their public launch provided deeper insight into the company’s position within the global orthopaedic trauma space. We reviewed Medartis’ 2017 and 2018 strategic announcements, and spoke with leadership to get a better sense of the company’s recent and future movement.

Page Navigation
First